GlassScriptPhysician profile
Stephen J Harney
NPI 1124029269
$2,708.11
in general payments reported to CMS, 2019-2025
20 companies · $655 in 2025
The $655 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $202 · 2021: $511 · 2022: $250 · 2023: $231 · 2024: $481 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,366.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $395.10 | 2019-2021 | |
| Coopervision INC. | $340.95 | 2019-2025 | Clariti Contact Lens, Misight Contact Lens, Myday Contact Lens |
| Tarsus Pharmaceuticals, INC. | $338.20 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $311.50 | 2019-2025 | Total30, Tryptyr, Rocklatan |
| Johnson & Johnson Vision Care, INC. | $278.63 | 2020-2025 | |
| Bausch & Lomb Americas INC. | $239.42 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Menicon America INC | $98.04 | 2022 | |
| Novartis Pharmaceuticals Corporation | $95.21 | 2019-2021 | |
| Sight Sciences, INC. | $92.52 | 2020-2024 | Tearcare System |
| Rxsight INC | $82.73 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Sun Pharmaceutical Industries INC. | $70.23 | 2025 | |
| Optovue, INC. | $49.56 | 2019 | |
| Shire North American Group INC | $46.37 | 2019 | |
| Dompe US, INC. | $46.08 | 2025 | Oxervate |
| Abbvie INC. | $44.18 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $43.54 | 2024 | Izervay |
| Allergan, INC. | $42.96 | 2021-2022 | |
| Glaukos Corporation | $38.18 | 2023 | Kxl1b-Ce-Marked Kxlsystem, Kxl System (Not Refurbished) |
| Oyster Point Pharma, INC. | $31.46 | 2022 | |
| Lombart Brothers, INC. | $23.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Harney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.